CF PharmTech, Inc. (2652.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in HKDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HKD m | - | - | - | - | - | - | - | - |
| Operating profit | HKD m | - | |||||||
| Net profit | HKD m | - | - | - | - | - | - | - | - |
| EPS reported | HKD | - | |||||||
| Operating cashflow per share | HKD | - | |||||||
| Capex per share | HKD | - | |||||||
| FCF per share | HKD | - | |||||||
| Free cash flow | HKD m | - | |||||||
| Net debt | HKD m | - | |||||||
| Book value equity | HKD m | - | |||||||
| Book value per share | HKD | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | HKD | - |
Financial summary
Financials in HKDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free